Navigation Links
Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
Date:5/13/2010

PARSIPPANY, N.J., May 13 /PRNewswire/ -- Ferring Pharmaceuticals Inc. announces that Grammy Award winner Gloria Gaynor will serve as the national spokesperson for the company's hyaluronic acid treatment therapy, EUFLEXXA® (1% sodium hyaluronate), for the pain associated with knee osteoarthritis (OA).  The announcement comes as Gaynor celebrates the 30th anniversary of her number one hit single, "I Will Survive."  Gaynor has been nicknamed the "Queen of Disco" and her songs and iconic voice define a generation.    

Gaynor was diagnosed with knee osteoarthritis in 1984, when she was 41 years old. She tried many options from ice packs to pain medications. In 2009, after her doctor recommended EUFLEXXA, Gloria began to feel relief.  

"I can walk up and down stairs with ease and stand with minimal pain -- even from a lower seat which was always very painful," said Gaynor.  "I am able to do more activities on stage now with less pain, which has always been my greatest passion."  In the last year, Gloria has also lost 55 pounds due to her increased activity and is still traveling and performing all over the world.

As the national spokesperson for EUFLEXXA, Gaynor hopes to increase awareness of knee OA and educate those who suffer from knee pain about the treatment options that are available to them.  "We are proud to have such an amazing entertainer as the face of our product," said Bill Garbarini, VP Orthopaedics/Urology Business Unit at Ferring Pharmaceuticals Inc.  "Gloria is as passionate as we are about providing education about osteoarthritis of the knee and possible treatment options for the associated pain."

About EUFLEXXA

EUFLEXXA® (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used in people who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.

IMPORTANT SAFETY INFORMATION

You should not receive this product if you have had any previous allergic reaction to EUFLEXXA® or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or if you have skin disease or infection around the injection site.

EUFLEXXA® is only for injection into the knee performed by a qualified doctor. After you receive this injection you may need to avoid activities such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour). The safety and effectiveness of repeat treatment cycles of EUFLEXXA® have not been established. The safety and effectiveness of EUFLEXXA® have not been shown in people under 18 years of age.

Side effects sometimes seen when EUFLEXXA® is injected into the knee joint were pain, swelling, skin irritation, and tenderness and these were generally mild and did not last long.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, international pharmaceutical company.  Ferring Pharmaceuticals offers a line of products in the U.S. market.  They include: BRAVELLE® (urofollitropin for injection, purified), MENOPUR® (menotropins for injection, USP) and REPRONEX® (menotropins for injection, USP), NOVAREL® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, 100 mg, FIRMAGON® (degarelix for injection), PROSED® DS (methenamine, phenyl salicylate, methylene blue, benzoic acid, hyoscyamine sulfate), and EUFLEXXA® (1% sodium hyaluronate).

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, orthopaedics, gastroenterology, obstetrics/gynecology, and infertility.  For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
2. Ferring Pharmaceuticals and Gene Security Network Partner to Test Advanced Preimplantation Genetic Diagnosis (PGD) Technology
3. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
4. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
5. Ferring Pharmaceuticals Unveils Six-Month Efficacy Data for EUFLEXXA(R) for the Treatment of Osteoarthritis Knee Pain
6. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
7. deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
8. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2010 First Quarter Earnings Conference Call on Monday, May 17, 2010 at 9:30 a.m. ET
9. Jazz Pharmaceuticals Announces Public Offering of Common Stock
10. China Yongxin Pharmaceuticals is Selected as one of the Qualified Pharmaceutical Distributors for Jilin Province
11. Epix Pharmaceuticals, Inc. Announces Additional Information Concerning the May 28, 2010 Auction Sale of EP-2104R MRI Imaging Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... -- Clarifying Vision - Prospects and Developments ... Care What can be expected from the ... at the fastest rates? This visiongain report ... opportunities and prospects. ,Our 190-page report ... lucrative areas in the industry and the future market ...
(Date:5/23/2016)... 23, 2016 Experts from various ... Medicine and the role of technology in innovative ... The First International Conference of VPS-Penn Medicine opened in ... and presence of Sheikh Nahyan bin Mubarak Al Nahyan, Minister ... Medicine, which helps provide personalized medicine and tailor-made healthcare in ...
(Date:5/23/2016)... , May 23, 2016   Purdue Pharma ... into an agreement with Egalet Corporation and Acura ... As part of the agreement the companies will ... enable all three companies to develop and sell ... "This agreement reflects the commitment of Purdue ...
Breaking Medicine Technology:
(Date:5/24/2016)... , ... May 24, 2016 , ... Mental health watchdog ... the Church of Scientology and renowned professor of psychiatry Thomas Szasz, is continuing its ... “Psychiatry: An Industry of Death” exhibit in Atlanta, Georgia. The opening of the exhibit ...
(Date:5/24/2016)... ... May 24, 2016 , ... Loma Linda University Health ... adult hospital and expanded Children’s Hospital. Over 3,000 people looked on as the shovels ... out the event photo slidehsow. , During the program, Richard H. Hart, MD, ...
(Date:5/24/2016)... ... May 24, 2016 , ... Backed ... data logger for each job, ensuring the best suited solution to meet regulatory ... data loggers at their lab in Istanbul. , Metroloji Okulu specializes in MadgeTech’s ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Growing in ... growing trend, more gluten-free products are available and easily accessible. Whether someone chooses to ... to cater to a certain diet, King Kullen Grocery stocks their shelves with many ...
(Date:5/24/2016)... ... May 24, 2016 , ... The ... 9.3 million people, or 10% over last year, according to data in the ... group policies was comparatively stable, with a slight decrease in risk-based groups and ...
Breaking Medicine News(10 mins):